Bio Essence (BIOE) Income from Continuing Operations (2020 - 2026)
Bio Essence (BIOE) recorded quarterly Income from Continuing Operations of 205373.0 in Q1 2026, down 80.04% quarter-over-quarter from 1029087.0 in Q4 2025, and up 199.82% on a YoY basis from 68499.73 in Q1 2025.
Bio Essence (BIOE) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Bio Essence's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 205373.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 199.82% year-over-year to 205373.0; the TTM figure through Mar 2026 stood at 1307322.0 (up 179.3% YoY), while the FY2025 annual figure was 896197.0, up 157.24% from the prior year.
- Income from Continuing Operations was 205373.0 for Q1 2026 at Bio Essence, down from 1029087.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1029087.0 in Q4 2025 to a low of 1199493.0 in Q3 2024.
- Historically, Income from Continuing Operations has averaged 82155.12 across 5 years, with a median of 105050.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations sank 1041.83% in 2024, then surged 3833.58% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 68664.0 in 2022, then tumbled by 366.59% to 183048.0 in 2023, then jumped by 84.94% to 27563.0 in 2024, then soared by 3833.58% to 1029087.0 in 2025, then plunged by 80.04% to 205373.0 in 2026.
- The last three Income from Continuing Operations figures came in at 205373.0 (Q1 2026), 1029087.0 (Q4 2025), and 12998.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Bio Essence | - | - | 319,353.00 | 205,373.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 205,373.00 |
| Dec 31, 2025 | 1.03 Mn |
| Sep 30, 2025 | 12,998.00 |
| Jun 30, 2025 | 59,864.00 |
| Mar 31, 2025 | -205,752.00 |
| Dec 31, 2024 | -27,563.00 |
| Sep 30, 2024 | -1.20 Mn |
| Jun 30, 2024 | -215,678.00 |
| Mar 31, 2024 | -122,986.00 |
| Dec 31, 2023 | -183,048.00 |
| Sep 30, 2023 | -105,050.00 |
| Jun 30, 2023 | -93,443.00 |
| Mar 31, 2023 | -23,064.00 |
| Dec 31, 2022 | 68,664.00 |
| Sep 30, 2022 | -199,233.00 |
| Jun 30, 2022 | -164,193.00 |
| Mar 31, 2022 | -233,120.00 |
| Dec 31, 2021 | -90,634.00 |
| Sep 30, 2021 | -183,037.00 |
| Jun 30, 2021 | -163,538.00 |